Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Tilt Investment Management Holdings PBC

Tilt Investment Management Holdings PBC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 437 shares of the biopharmaceutical company’s stock after selling 129 shares during the quarter. Tilt Investment Management Holdings PBC’s holdings in Regeneron Pharmaceuticals were worth $384,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC raised its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after buying an additional 669,517 shares during the period. Northern Trust Corp grew its position in Regeneron Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after acquiring an additional 34,326 shares in the last quarter. Morgan Stanley raised its stake in shares of Regeneron Pharmaceuticals by 2.7% during the third quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after purchasing an additional 25,792 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Regeneron Pharmaceuticals by 0.3% during the third quarter. Bank of New York Mellon Corp now owns 967,414 shares of the biopharmaceutical company’s stock worth $796,142,000 after purchasing an additional 2,666 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $697,296,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on REGN. Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 12th. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. UBS Group lifted their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $976.41.

Regeneron Pharmaceuticals Price Performance

REGN stock traded down $3.63 on Thursday, hitting $897.56. 248,925 shares of the company’s stock traded hands, compared to its average volume of 492,167. The stock has a market cap of $98.52 billion, a price-to-earnings ratio of 25.93, a P/E/G ratio of 2.58 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The stock has a fifty day moving average of $955.19 and a 200-day moving average of $890.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $10.96 EPS. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.58 EPS for the current fiscal year.

Insider Activity

In related news, Director Joseph L. Goldstein sold 2,707 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total value of $2,571,650.00. Following the transaction, the director now owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at approximately $1,325,338. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Joseph L. Goldstein sold 2,707 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the completion of the transaction, the director now directly owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The disclosure for this sale can be found here. Insiders sold a total of 13,729 shares of company stock valued at $13,124,641 over the last three months. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.